ForPatients
by Roche

Hemophilia A

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN4)

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

Trial Status	Trial Runs In	Trial Identifier
Completed	6 Countries	NCT03020160 2016-001094-33, HAVEN4 BO39182

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, open-label, non-randomized study will assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg/kg) every 4 weeks in participants with hemophilia A with or without inhibitors against factor VIII (FVIII). The study consists of 2 parts: a pharmacokinetic (PK) run-in part followed by an expansion part.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03020160 2016-001094-33, HAVEN4 BO39182
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=12 Years	No